-
Member Announcements
- CDRD Partners with Université de Sherbrooke to Leverage R&D Expertise in BC and Quebec
- Celator ® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
- New BC Showcase launched in portal for Canadian clinical research capabilities Database will help Canada regain its position as a leading competitive nation for clinical trials
- Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
- Celator ® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
- CDRD Partners with Universite de Sherbrooke to Leverage R&D Expertise in BC and Quebec
- SOHO Biotech Inc. to Participate in 2015 Medical Device Mission to Taiwan
- Austin Wang, Grade 11 Student from Vancouver, Recognized for Environmental Biotech
- DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015
- ProNAi Therapeutics Files Registration Statement for Proposed Initial Public Offering
- STEMCELL Technologies Named Company of the Year by BIOTECanada
- Qu Biologics Appoints Jim Pankovich as Vice President, Clinical Operations and Drug Development
- JOSEPH GARCIA RECOGNIZED AS A VISIONARY LEADER IN BIOTECANADA’S 2015 GOLD LEAF AWARDS
- Vancouver Company Wins Prestigious National Award
- Mapping BC’s Path to Personalized Medicine Global experts discuss and recommend best practices for the integration of personalized medicine into healthcare
- RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC
- Sirona-Biochem-Corp.-2015-06-03_141817.aspx
- Xenon Pharmaceuticals To Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference
- Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
- Aquinox Pharmaceuticals to Present at 2015 Jefferies Global Healthcare Conference
- Charles Garcia joins StarFish Medical as new Vice President, Business Development
- Xenon Pharmaceuticals Appoints Steven Gannon to its Board of Directors
- Access to New Medicines in Public Drug Plans: Canada and Comparable Countries Report
- RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
- Sirona-Biochem-Corp.-2015-05-20_083407.aspx
- Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
- Aquinox Pharmaceuticals Announces First Quarter 2015 Financial Results
- Qu Biologics Granted European Patent for Use of Bacterial Compositions for the Treatment of Cancer
- ANNOUNCEMENT OF 2015 AWARD WINNERS First Annual MDDC Awards for Excellence in Biomedical Engineering
- (MSI) Completes Recruitment of Phase 2 Trial for its Novel Treatment STRADAâ„¢ for Major Depressive Disorder (MDD)
- Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives
- Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 KINSHIP Trial of AQX-1125 in Atopic Dermatitis
- More Federal Wage Subsidies Announced for Canadian Biotech Students
- AEQUUS AND CORIUM ENTER INTO PRODUCT DEVELOPMENT COLLABORATION FOCUSED ON CNS
- Aquinox Pharmaceuticals to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference
- Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn’s Disease Clinical Trial
- Biolux-Research-Ltd.-2015-04-23_105217.aspx
- National Access Project for Cancer Testing Gains Momentum
- SOHO Biotech Inc. to Release Histamine Elisa Kits for Testing Fish Poisoning
- RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
- Aquinox Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
- Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)
- Biolux-Research-Ltd.-2015-04-01_115834.aspx
- Qu Biologics Granted U.S. Patent for Use of E. coli to Treat Crohn’s Disease
- Northview-Ventures-2015-03-27_100217.aspx
- Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride Lowering by Silencing of ApoC3 and ANGPTL3 Genes
- Qu Biologics Begins Research Collaboration with the University of Rochester, New York
- RepliCel Life Sciences Meets with Japanese Pharmaceutical and Medical Devices Agency (PMDA)
- SORIN GROUP SIGNS MERGER AGREEMENT WITH CYBERONICS
- Aequus-Pharmaceuticals-2015-03-17_063918.aspx
- Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director
- XENON PHARMACEUTICALS APPOINTS DR. RICHARD H. SCHELLER TO ITS BOARD OF DIRECTORS
- Aquinox Pharmaceuticals Announces Year End 2014 Financial Results
- RepliCel Life Sciences in Japan for Key Industry Meetings
- XENON PHARMACEUTICALS REPORTS 2014 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call
- Member Announcements">Aquinox Pharmaceuticals to Announce Year End 2014 Financial Results and Host Conference Call on March 16, 2015
Member Announcements
- Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2014 Financial Results and Provide Corporate Update
- Biolux-Research-Ltd.-2015-03-06_104449.aspx
- Sirona-Biochem-Corp.-2015-03-04_080855.aspx
- Qu Biologics Named Life Sciences BC Growth Stage Company of the Year
- Contextual Genomics and the Personalized Medicine Initiative Welcome Pfizer Canada to Consortium for National Access Project for Cancer Testing
- 17th Annual LifeSciences BC 2015 Award Winners, presented by FARRIS
- Patented Canadian Technology that Measures Heart Rate and Blood Oxygen Levels through Smartphones and Other Mobile Devices Approved by Health Canada
- LGTmedical Announces Issuance of U.S. Patent for Kenek Coreâ„¢ Audio Waveform Technology
- Aquinox Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference
- Aequus Pharmaceuticals Becomes Reporting Isuuer
- XENON PHARMACEUTICALS’ PARTNER TEVA TO INITIATE PHASE 2b CLINICAL TRIAL OF TV-45070 IN POST-HERPETIC NEURALGIA
- NSERC Brockhouse Canada Prize Honours Medical Isotope Team CycloMed99
- Response Biomedical Corp. Announces Milestone Achievement in Co-Development Collaboration
- Northern Lipids Inc is pleased to announce the appointment of Dr. Norbert Maurer as Director of R&D
- Global News – B.C. company providing free genomics cancer test to 2000 Canadians
- Contextual Genomics and the Personalized Medicine Initiative Receive Funding from AstraZeneca for National Access Project for Cancer Testing
- Notice of Upcoming Funding Opportunity 2015 Large-Scale Applied Research Project Competition Natural Resources and the Environment: Sector Challenges – Genomic Solutions
- Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene
- Interprovincial collaboration launched to advance clinical research
- RepliCel Life Sciences to Present at Biotech Showcase 2015 in San Francisco
- Canadian Team Demonstrates Solution to Medical Isotope Crisis
- Pfizer Acquires Redvax GmbH
- Member Announcement
- Lilly Finalizes Novartis Animal Health Acquisition
- RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement
- Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
- Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
- Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
- Industry News
- Lifescience BC Publications
-
Industry Publications
B.C. Industry News
Business in Vancouver – Former Aspreva executives’ new company nets $56 million in private placement
February 18, 2014
By Nelson Bennett
Aurinia Pharmaceuticals Inc. (TSX-V:AUP), a Victoria-based biotech whose team includes the founders of British Columbia’s most successful biopharmaceutical companies – Aspreva Pharmaceuticals – has secured $56 million in private placements.
Aurinia is developing a drug for treating lupus-related kidney infection.
The financing was led by venBio, New Enterprise Associates, Redmile Group, RA Capital Management, Great Point Partners and Apple Tree Partners.
Other institutional investors include existing shareholders Lumira Capital, ILJIN Life Science Co. Ltd. and Difference Capital.
The company said it planned to use the financing to move its chief drug candidate – voclosporin – into stage two clinical trials. The company also plans to file for listing on the Nasdaq by the end of this year.
“This has provided us with the necessary resources to begin implementing our strategic plan, including the launch of a phase 2B study of voclosporin in lupus nephritis,†said Aurinia CEO Stephen Zaruby.
According to Aurinia, voclosporin has potential as a drug for preventing organ rejection in kidney transplant patients. But the company plans to focus on using it to treat lupus nephritis – inflammation of the kidney caused by lupus erythematosus.
Aurinia is a late-stage biopharmaceutical company whose executive team includes former Aspreva executives.
Former Aspreva co-founder Richard Glickman is Aspreva’s chairman. Aurinia COO Michael Martin was a key member of the Aspreva team that put together what was to become the biggest acquisition in B.C. biotech history, when Aspreva sold to the Galenica Group for $915 million in 2007.
@nbennett_biv